The compliance with secondary prevention and the relationship with the long-term outcome in patients undergoing percutaneous coronary intervention
- VernacularTitle:经皮冠状动脉介入治疗术后患者对二级预防的依从性及其与长期预后的关系
- Author:
Zhongyu ZHU
;
Chuanyu GAO
;
Yan CHEN
;
Zhenmin NIU
;
Kejun HUANG
;
Yuhao LIU
;
Muwei LI
;
Yu XU
;
Han ZHOU
;
Jing ZHANG
;
Jiaying ZHANG
- Publication Type:Journal Article
- Keywords:
Percutaneous coronary intervention;
Secondary prevention;
Compliance;
Long-term out-come
- From:
Clinical Medicine of China
2008;24(6):550-553
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the compliance of secondary prevention and the relationship with the long-term outcomes in patients undergoing percutaneous coronary intervention(PCI).Methods 589 patients undergoing PCI were followed-up,and factors including major adverse cardiac events(MACE)),smoking status and the usage of antiplatelet agents,angiotensin converting enzyme inhibitor(ACEI)/angiotensin Ⅱ receptor blocker(ARB),statins,beta blocker,calcium channel blocker and nitrates were recorded.Results The average follow-up time was 18.92 months.At discharge,588 patients(99.83%)were prescribed clopidogrel for(7.89±4.96)months;there were 31 patients(5.26%)who completely discontinued antiplatelet therapy during follow-up.At discharge,the prescription rate of aspirin,ACEI/ARB,beta blocker,statins,calcium channel blocker and nitrates was 98.98%,41.94%,63.50%,83.02%,19.69%and 46.52%respectively,whereas at follow-up,these were decreased to 94.4%,35.99%,55.86%,65.89%,17.49%and 35.31%.At follow-up,there were still 105 current smokers(17.83%).Complete cessation of antiplatelet therapy and current smoking were related to the increased risk of non-fatal myocardial infarct(9.68%v.s.1.08%,P＜0.01);smoking(4.76%v.s.0.83%,P＜0.01)andMACE(19.35%v.s.6.45%,P＜0.01);smoking(11.43%v.s.6.20%,P＜0.05).Conclusion Most patients can adhere to secondary prevention during follow-up,however,the compliance with secondary prevention should be improved further.Cessation of antiplatelet therapy and current smoking contribute to poor prognosis.
